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Background: Deep vein thrombosis (DVT) or venous thromboembolus (VTE), is a common complication
with orthopedic surgery and remains a serious problem even with multiple medications available for
prophylaxis. Enoxaparin and fondaparinux are widely accepted in North America, Australia, and Europe
although, a lack of evidence still remains to determine which is more effective in DVT prophylaxis in
orthopedic surgery. This systematic review seeks to determine whether fondaparinux is more effective than
enoxaparin in DVT prophylaxis.
Methods: A systematic literature search using multiple databases focusing on articles from professional
journals, position statements, information from pharmaceutical manufacturers and CDC statistics were the
primary sources for this study.
Hypothesis: Fondaparinux is more effective than enoxaparin in DVT prophylaxis, with a lower bleeding risk,
and reduction of patient death.
Results: Six studies were evaluated to determine the effectiveness of fondaparinux compared to enoxaparin.
Fondaparinux was compared to enoxaparin in double-blinded randomly assigned trials using subjects over 18
years of age who were scheduled to undergo orthopedic surgery of the lower extremity within 48 hours of
admission. Potential subjects were excluded from the studies if they were involved in multiple trauma affecting
more than one organ system, pregnancy, active bleeding, history of hemorrhagic stroke, bleeding disorder,
hypersensitivity to heparin, serum creatinine above 2 mg/dl, and a platelet count below 100,000 per cubic
millimeter. In all studies day 1 was defined as the day of surgery.
Conclusion: Fondaparinux is more effective at DVT prophylaxis than enoxaparin and should be considered a
preferential agent in high DVT risk orthopedic surgery. Further randomized trials with long term outcomes
(>30 days), are needed to evaluate benefit to risk of longer term prophylaxis post orthopedic surgery.
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Abstract 
Background: Deep vein thrombosis (DVT) or venous thromboembolus (VTE), is a 
common complication with orthopedic surgery and remains a serious problem even with 
multiple medications available for prophylaxis. Enoxaparin and fondaparinux are widely 
accepted in North America, Australia, and Europe although, a lack of evidence still remains 
to determine which is more effective in DVT prophylaxis in orthopedic surgery. This 
systematic review seeks to determine whether fondaparinux is more effective than 
enoxaparin in DVT prophylaxis.  
Methods  
A systematic literature search using multiple databases focusing on articles from professional 
journals, position statements, information from pharmaceutical manufacturers and CDC 
statistics were the primary sources for this study.  
Hypothesis:  Fondaparinux is more effective than enoxaparin in DVT prophylaxis, with a 
lower bleeding risk, and reduction of patient death.  
Results: Six studies were evaluated to determine the effectiveness of fondaparinux 
compared to enoxaparin. Fondaparinux was compared to enoxaparin in double-blinded 
randomly assigned trials using subjects over 18 years of age who were scheduled to undergo 
orthopedic surgery of the lower extremity within 48 hours of admission. Potential subjects 
were excluded from the studies if they were involved in multiple trauma affecting more than 
one organ system, pregnancy, active bleeding, history of hemorrhagic stroke, bleeding 
disorder, hypersensitivity to heparin, serum creatinine above 2 mg/dl, and a platelet count 
below 100,000 per cubic millimeter. In all studies day 1 was defined as the day of surgery.  
Conclusion: Fondaparinux is more effective at DVT prophylaxis than enoxaparin and 
should be considered a preferential agent in high DVT risk orthopedic surgery. Further 
randomized trials with long term outcomes (>30 days), are needed to evaluate benefit to risk 
of longer term prophylaxis post orthopedic surgery.  
Keywords: hip fracture, total hip arthroplasty, total knee arthroplasty, venous 
thromboembolism, pulmonary embolism, enoxaparin (Lovenox), fondaparinux (Arixtra), 
orthopedic surgery, factor Xa inhibitor. 
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Efficacy of Fondaparinux Compared to Lovenox for Deep 
Vein Thrombosis Prophylaxis in Lower Extremity 
Orthopedic Surgery 
Introduction 
 
 Patients undergoing lower extremity orthopedic surgery (hip fracture, hip 
replacement, knee replacement), are in the highest category for postoperative venous 
thromboembolism and pulmonary embolus.1 This exaggerated risk for postoperative deep 
vein thrombosis2, 3 where 45-57% of total hip replacement (THR) patients, 40-84% of total 
knee replacement (TKR), and 36-60% of hip fracture surgery (HFS) patients develop DVT, 
often presents even with appropriate prophylaxis.4  
 The US Center for Disease Control (CDC) estimated in 2004, that there were over 
320,000 hospital admissions for HFS, 234,000 THR surgeries, and 478,000 TKR surgeries.2 
Approximately 1 in 5 hip fracture patients dies within a year of their injury, often from 
pulmonary embolus (PE), with higher mortality seen in elderly female patients in the first 4 
months after surgery.2 With the aging of the US population, HFS alone is expected to double 
over the next 30 years.3  
 Still, DVT prophylaxis is somewhat surprisingly underutilized in the orthopedic 
setting, for those at highest risk, the elderly. Ennis, et al reported, in a retrospective study 
that, over 46% of patients received either no pharmacological prophylaxis, or only aspirin for 
DVT prophylaxis. The study’s female subjects’ average age was 83 years while the male 
subjects’ average age was 78 years.5 
 Postoperative bleeding risk is often the largest concern in orthopedic surgery, with 
some evidence pointing to DVT or PE as a more likely occurrence. Lopez-Jimenez, et al 
found in a study of VTE in the very elderly, a low incidence of fatal bleeding (0.8%) but a 
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significantly higher incidence of fatal PE (3.7%). The authors concluded, “there seems to be 
more reason to be concerned about fatal PE than about bleeding in elderly patients with 
VTE”.6  
 Returning patients to active, healthy productive lives is the goal of any procedure and 
those mentioned in this paper are no different. Aging of the U.S. population will undoubtedly 
increase HFS, THA, TKR rates underlining the need for more effective DVT prophylaxis 
perioperatively.  
 
Purpose of study 
 
 This systematic review was done to evaluate the effectiveness in lower extremity 
orthopedic surgery patients, of fondaparinux (Arixtra) compared to enoxaparin (Lovenox) in 
DVT prophylaxis. Fondaparinux (Arixtra) was the first pentasaccharide, a class of 
medications that cause the selective inhibition of factor X without direct activity against 
thrombin, to be approved, for use in the US. Fondaparinux is 100% bioavailable, exhibits a 
linear pharmacokinetic profile, reaches half maximal plasma concentration within 25 
minutes, and has a half life of 15 -17 hours, allowing for once daily administration.7 This 
novel approach to therapy is not without concern, as there is no known antidote to reverse the 
effects of fondaparinux at this time.  
 Due to its ease of administration and mechanism of action, fondaparinux is the focus 
of thrombosis prophylaxis in orthopedic surgery, cardiology, oncology, and abdominal 
surgery programs throughout the US and Europe. It should be noted that, pulmonary 
embolism (PE), was not the primary focus of this systematic review but is addressed because 
it was considered a venous thromboembolus in the majority of the literature reviewed.  
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Significance 
 
 The aging of the US population represents an opportunity for clinicians and 
researchers to determine efficacious treatments that benefit the patient, improve outcomes, 
and decrease the incidence of DVT, PE, and death after orthopedic surgery. Perioperative 
outcomes are the focus of this paper however, Gordois, et al found that the use of 
fondaparinux led to long term cost savings (5 years post surgery) in the UK Public Health 
System. Fondaparinux was found to have a lower rate of clinical VTE (33.4 vs 53.4 per 1000 
patients), lower VTE-related deaths (3.9 vs 7.1 per 1000 patients), and discounted cost (₤219 
vs £246 per patient at 5 years). It was also found to prevent 2640 VTE events and 400 VTE-
related deaths annually.8 Fondaparinux is now the preferred agent for DVT prophylaxis in the 
UK.8  
 The fastest growing segment of the US population is those 80 years and older. 
Enders, et al report, that the incidence of VTE increases with age, with an estimated 200-fold 
increase in risk between the ages of 20 and 80 years, the sharpest increase being noted after 
40 years of age.9 Treatments for the prevention of DVT and PE in the elderly population are 
especially important to improve outcomes after orthopedic surgery.  
 
Methods and Materials 
 An exhaustive literature search was conducted, using the following search engines 
CINAHL, Web of Science, Ovid, Medline, and MD Consult. Inclusion criteria: randomized 
control trials published since 2000 comparing fondaparinux and enoxaparin in orthopedic 
surgery, English language, and multicenter multicountry randomized control trials were 
preferred for this study. Exclusion criteria included meta-analyses, retrospective studies, and 
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articles published prior to 2000. All randomized control trials available were used for this 
review due to the limited number of studies. Literature review included information from 
professional journals, the US Center for Disease Control, and pharmaceutical manufacturers. 
 
Results 
 
 A dose-ranging study authored by Turpie, et al, looked at using fondaparinux in the 
prevention of deep vein thrombosis after total hip replacement.10 The study was performed to 
determine the optimal dosing for Phase III Clinical trials and included information which was 
used in future studies involving fondaparinux.  
 Patients were randomized during the double-blinded trial and consisted of 933 
subjects, undergoing total hip replacement surgery. Study drugs were given for 10 days or 
until mandatory bilateral venography was performed, after a minimum of 5 days. Subjects 
were placed on 0.75 mg, 1.5 mg, 3.0 mg, 6.0 mg, or 8.0 mg of fondaparinux once daily or 
enoxaparin 30 mg every 12 hours.  
 This trial showed RRR of 82% (P=0.01) for the 3.0 mg fondaparinux group and 29% 
(P=0.51) for the 1.5 mg fondaparinux group. Enrollment in the 6.0 mg and 8.0 mg groups 
was discontinued because of major bleeding episodes. In the comparison between the 3.0 mg 
fondaparinux group and the 30 mg enoxaparin group little difference was noted. The authors 
determined fondaparinux has the potential to significantly improve the prevention of VTE 
compared with low molecular weight heparin (LMWH).    
 Another article, the European Pentasaccharide Hip Elective Surgery Study 
(EPHESUS),11 was the first large scale trial to compare the effectiveness of fondaparinux to 
enoxaparin in orthopedic surgery. The double-blinded, randomly assigned study enrolled 
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2309 patients from 73 medical centers in 16 European countries, and placed them into two 
groups: enoxaparin 40 mg once daily with the first dose given before surgery, or 
fondaparinux 2.5 mg once daily started postoperatively. The trial arm groups were equally 
divided between the two regimens (fondaparinux n=1140 and enoxaparin n=1133). Each 
medication was administered through day 9 and patients followed through day 11. Patients 
qualified for the protocol if they were age 18 or older, having primary elective hip 
replacement, or revision of at least 1 component of a previously implanted total hip 
prosthesis. Subjects were assessed for DVT by bilateral venography, between day 5 and 11 
(no longer than 2 days after the last dose of study medication), and for symptomatic PE by 
lung scan, pulmonary angiography, helical CT, or at autopsy.  
 Use of sequential compression devices (SCDs), dextran, thrombolytic treatment, and 
any other anticoagulant agents were prohibited. Centers were also instructed to avoid giving 
patients aspirin or non-steroidal anti-inflammatory agents when possible. Compression 
stockings and physical therapy and early mobilization were recommended. The findings 
showed fondaparinux caused a RRR of 55.9% (95% CI, 33.1-72.8; p<0.0001) with no 
difference in incidence of major bleeding or death (11).  
 The PENTATHLON 2000 Trial12 was the next in this series of studies to compare 
fondaparinux and enoxaparin for the prevention of VTE. This trial enrolled 2275 patients in 
149 medical centers in North America and Australia, and compared enoxaparin 30 mg twice 
daily to 2.5 mg fondaparinux once daily. Medications given in this trial were administered 
after surgery, with the first dose of fondaparinux given 4-8 hours post surgery and first dose 
of enoxaparin given between 12-24 hours post surgery, in accordance with manufacturer’s 
recommendations.  Subjects received study medication for 5-9 days post surgery and were 
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followed through day 11. Mandatory bilateral venography was performed between day 5-11 
post surgery with symptomatic PE evaluated by lung scan, pulmonary angiography, helical 
CT, or at autopsy. Follow-up was completed between day 35 and day 49 post procedure. This 
was the first trial to compare both medications in the postoperative setting. Approximately 
70% of subjects were included in the efficacy analsysis, an improvement over the EPHESUS 
trial.  
 Study results showed that fondaparinux caused a RRR of 26.3% (95% CI, -10.8-
+52.8; p=0.099), but was not significantly more effective than enoxaparin in reducing the 
risk of symptomatic VTE. Fondaparinux was however, significantly more effective in 
reducing the total number of VTE by day 11. The authors found a clinically important lower 
risk with fondaparinux, where no increase in clinically relevant bleeding or incidence of 
major bleeding or death was noted. 
 The Pentasaccharide in Hip-Fracture Surgery Study (PENTHIFRA)13, a randomly 
assigned, double-blinded trial, released in November 2001, compared enoxaparin 40 mg once 
daily, administered preoperatively to fondaparinux 2.5 mg once daily, administered 
postoperatively. Subjects were enrolled through 100 medical centers in 21 countries and 
included 1711 consecutive patients aged 18 or older. Subjects received study medications up 
to day 9 and were followed through day 11. As with the PENTATHLON study, mandatory 
bilateral venography was performed between day 5 and day 11 to determine the presence of 
DVT. Patients were followed up in person, by phone, or mail between day 35 and 49. Again, 
investigators could extend prophylaxis with any appropriate therapy but only after 
venography had been done. Symptomatic PE was evaluated by lung scan, pulmonary 
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angiography, helical CT, or at autopsy. If VTE was present at any point during the study, the 
treatment course was decided by the investigator.  
 The authors found the VTE rate by day 11 was 8.3% in the fondaparinux group and 
19.1% in the enoxaparin group, yielding a RRR of 56.4% (95% CI, 39.0 to 70.3%; p<0.001). 
They found no difference in major bleeding or death and no difference between the groups in 
symptomatic VTE with a low rate of 6.5%. The number of patients treated for VTE by day 
11 was lower in the fondaparinux group (6.1%) than in the enoxaparin group (11.7%). By 
day 49 the incidence of symptomatic VTE was similar in both groups (2.0% in fondaparinux 
and 1.5% in enoxaparin). It should be noted that, even with appropriate use of study 
medications, 38 patients (4.6%) in the fondaparinux group, and 42 patients (5.0%) in the 
enoxaparin group had died by day 49. The authors attribute the efficacy of fondaparinux to 
“its ability to inhibit factor Xa rapidly and selectively, its predictable linear 
pharmacokinetics, and its relatively long half-life, which permits the drug to achieve an 
antithrombotic effect for 24 hours” (PENTHIFRA Study).  
 The Pentasaccharide in Major Knee Surgery Trial (PENTAMAKS)14 compared 
fondaparinux 2.5 mg daily, initiated 6 ± 2 hours postoperatively (second dose given 12 hours 
or more after the first), to enoxaparin 30 mg twice daily, initiated 12-24 hours 
postoperatively (based on manufacturer’s recommendations), for 5-9 days. The randomized 
double-blinded study enrolled 1049 patients from 64 centers in North America. Patients were 
followed through day 11 and had mandatory bilateral venography performed between day 5 
and 11, but no longer than 2 days after the final dose of study medication. Patients in the trial 
were at least 18 years old and were undergoing elective major knee surgery. 
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 Symptomatic PE was evaluated by lung scan, pulmonary angiography, helical CT, or 
at autopsy. Follow-up, as in the previously mentioned trials, was performed between day 35 
and day 49 post surgery via telephone, mail, or in person. Also, patients were to report any 
signs or symptoms of VTE or bleeding. Investigators could extend prophylaxis during 
follow-up with any available therapy after venography had been performed. In the presence 
of VTE during the study, treatment was determined by the investigator.  
 Results of the PENTAMAKS showed fondparinux was superior to enoxaparin in the 
prevention of VTE. The fondaparinux group had an incidence of VTE of 12% compared to 
27.8% in the enoxaparin group, yielding an ARR of 55.2% (95% CI, 36.2 to 70.2%; 
P<0.001). The superiority of fondaparinux in primary efficacy was consistent according to 
age, sex, BMI, type of anesthesia, type of surgery (primary or revision), use or nonuse of 
cement, and whether or not patients experienced previous VTE. The number of patients 
treated for VTE by day 11 was significantly lower in the fondaparinux group (15.1 %) when 
compared to the enoxaparin group (25.1%, P<0.001). No instances of fatal bleeding were 
seen, in either group, and no difference in mortality was noted between the 2 medication 
groups. The authors concluded fondaparinux is significantly more effective than enoxaparin 
in preventing VTE after elective major knee surgery.  
 The trials previously mentioned, looked at the immediate postoperative course in 
DVT prevention. None addressed the issue of appropriate duration of DVT prophylaxis. The 
PENTHIFRA Plus Trial15, released in 2003 did investigate this topic. The study authored by 
Ericksson, et al, enrolled 656 patients undergoing hip fracture surgery in a randomly 
assigned, placebo-controlled, double-blinded fashion, from 57 centers in 16 countries. 
Subjects received fondaparinux 2.5 mg daily or placebo, for an additional 19 to 21 days (after 
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initial 1 week, 6 to 8 days, prophylaxis with fondaparinux) post surgery to determine the 
efficacy of fondaparinux in extended DVT prophylaxis. Total DVT prophylaxis was 25 to 31 
days post surgery.  
 While this trial did not compare fondaparinux to enoxaparin in DVT prophylaxis, the 
important information regarding extended prophylaxis can not be overlooked. Several studies 
have shown the benefit of extended prophylaxis using enoxaparin but no other study has 
addressed this concerning fondaparinux. The authors found fondaparinux reduced the 
incidence of VTE from 35.0% (77/220) to 1.4% (3/208) with a RRR of 95.9% (95% CI, 
87.2%-99.7%; P<0.001) when compared to placebo. The fondaparinux group had a higher 
bleeding rate than the placebo group but, there were no differences between the 2 groups in 
regards to the incidence of clinically relevant bleeding.  
 The authors stated that, the results of this study would be easily reproducible because 
they chose not to exclude subjects with asymptomatic DVT at 7 days post surgery. They 
further stated that all patients with hip fracture surgery, not only high-risk groups, would 
benefit from an additional 1 month treatment with fondaparinux. Additionally, fondaparinux 
requires no monitoring of PT/INR or dose adjustment, with a high level of subject 
compliance being achieved.  
 
Discussion 
 The studies utilized in this systematic review were high quality, randomized, double-
blinded, and had good sample sizes. All of the studies used were multi-center, multi-country 
in nature and considered many possible outcomes and exclusion criteria for therapy. The 
studies relied on similar treatment regimens and the medications, fondaparinux and 
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enoxaparin, length of prophylaxis during hospital stay, evaluation techniques, and length of 
follow-up. 
 Several areas of concern were noted with the dose-ranging trial (Turpie, et al). The 
most easily identified problem is the number of subjects in the various treatment groups. The 
enoxaparin group had 260 subjects while the fondaparinux groups ranged from 52 (8.0 mg 
group) to 188 (1.5 mg group) subjects. Another concern is the number of potential subjects 
not included in the efficacy analysis. Only 64% of the original study subjects met the criteria 
for intention-to-treat and per-protocol analysis. Other studies reviewed for this paper used 
approximately 70% of subjects in the efficacy analysis. A larger percentage of subjects 
included in the analysis would make the results more accurate. 
 The EPHESUS Trial11 limitations were common to others presented. It is important to 
note that 6 out of 10 steering committee members were on the payroll of the sponsor of the 
study (GlaxoSmithKline - GSK), who was also responsible for performing the statistical 
analysis. This issue might lead one to question the objectivity of the study. Also, only 80% of 
patients had an adequate venogram which resulted in over 400 subjects being left out of the 
final statistical analysis. Finally, prolonged prophylaxis in over 50% of patients, likely 
prevented symptomatic VTE outside of the initial therapy window (day 5-11) but still within 
the prolonged follow-up period (day 35-49). Investigators could and did extend prophylaxis 
during follow-up with any available treatment and at the discretion of the investigator, 
leading to the potential that the follow up results may be skewed that future studies may 
reach inaccurate results and conclusions.  
 Problems with the PENTATHLON Trial12 are similar to those found in the 
EPHESUS trial where 6 of 10 members of the steering committee were again from the 
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sponsor with the sponsor likewise completing the statistical analysis. Additionally, a large 
number of patients (650 or 28.5%) in both treatment groups had no venography performed by 
day 11 or had a study that was inadequate. Moreover, subjects receiving a minimum of 1 
dose of study drugs were included in the analysis, possibly altering the VTE rate and the 
conclusions the authors reached.  
 The PENTHIFRA Study13 had similar shortcomings in that only 1 dose of study 
drugs was required to be included in the efficacy analysis. The potential bias on the steering 
committee, where 6 of 10 people were from the drug manufacturer (GSK) with the final 
statistical analysis also being done by the sponsor, remained present. Additionally in this 
study, only 25.6% of patients received the preoperative injection of enoxaparin due to 
emergent situations but these subjects were still included in the efficacy analysis. Lastly, 421 
patients or 24.6% had not been assessed by venography by day 11. This is a similar 
percentage seen in both the EPHESUS11 (20%) and PENTATHLON12 (28.5%) trials.  
 Limitations of the PENTAMAKS Trial14 are similar to those presented in this 
systematic review. Namely patients receiving only 1 dose of study medication were included 
in the efficacy analysis. The drug manufacturer was represented by 7 of 11 members of the 
steering committee and was responsible for final statistical analysis. Venography was not 
performed by day 11 in 310 out of 1049 patients (~30%), which is in line with other studies 
mentioned in this review.   
 The PENTHIFRA Plus Trial15 was not immune to areas of concern. Patient 
compliance was determined by reviewing written records from patients, caregivers, and 
community nurses. Alternatively, patients had to receive at least 19 doses of study drug to be 
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included in the efficacy analysis. However, when VTE was confirmed, study treatment was 
discontinued and replaced by another regimen at the investigator’s discretion.  
 This study had an open-label portion (initial 1 week prophylaxis) using fondaparinux. 
The authors did not use subjects that received other DVT prophylaxis, possibly exaggerating 
the results of the additional 3 weeks of prophylaxis with fondaparinux. The authors do report 
using a steering committee which designed the study, interpreted the results, and wrote the 
article, and a data monitoring committee and central adjudication committee which were 
independent of the sponsor.  
 All studies (except PENTHIFRA Plus) in this systematic review permitted 
prophylaxis at the discretion of the investigator once outside the treatment window (Day 5-9 
or follow-up at Day 11). While clinically and ethically appropriate, this may have altered 
results during the follow-up period (between day 35-49) and effected VTE rates in both 
groups.  
 Timing of medication administration with different recommendations from 
manufacturers, European (40 mg 12 h before surgery) compared to US (30 mg bid 12-24 h 
after surgery) dosing regimens, may produce results that cannot be standardized. Although, 
the dosing regimens were standardized for study purposes, the fact that the approved 
European regimen differs from the approved US dosage yields different results in clinical 
practice than those found in the study.  
 The majority of studies found a slightly higher bleeding risk with fondaparinux, likely 
due to its targeted mechanism of action in the coagulation cascade. On the other hand, the 
risk of heparin induced thrombocytopenia (HIT) is non-existent with fondaparinux. 
Warkintin, et al16, found poor reactivity of antibodies against platelet factor 4 (PF4) and also 
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determined that HIT would occur less frequently with fondaparinux compared with LMWH 
without developing thrombocytopenia. The authors also theorized, fondaparinux might be 
safe for patients with HIT induced by either LMWH or unfractionated heparin (UFH). They 
found that a low capacity for fondaparinux to form the antigens on PF4, may contribute to 
further reduce the most frequent immune-mediated adverse drug reaction associated with 
anticoagulant therapy.16   
   
Limitations of Study 
 Several limitations are noted in the systematic review of this topic. First and 
foremost, is the lack of studies to adequately assess the potential outcomes of using 
fondaparinux in the orthopedic surgery setting. The extensive literature review using multiple 
databases yielded less than 10 articles, one of which was a dose-ranging trial, with several 
having the same author as lead investigator (Eriksson and Lassen in particular). 
  It is difficult to overlook the possible influence which drug manufacturers held over 
the results of studies published on the use of fondaparinux in orthopedic surgery. All studies 
were sponsored by the manufacturer of fondaparinux (Sanofi, now GlaxoSmithKline) and 
had statistical analysis done by the sponsor. While this may be commonplace in research the 
impression it presents, is concerning.  
 Assessment of DVT by venography and PE by various tests is open to error, based on 
technique and interpretation by a radiologist. While venography remains the gold standard in 
determining DVT, other diagnostic tools, could appropriately be considered. The large 
number (up to 36%) of patients not receiving the mandatory venography by day 11 post 
surgery, in the studies presented here, carries a significant potential for error. 
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 Although the studies mentioned in this review differentiated between total, distal, and 
proximal DVT (which is more likely to embolize), the author chose not to provide a 
breakdown based on these categories. The focus of this review was to determine efficacy in 
DVT prophylaxis, not to determine which medication limited distal or proximal DVT 
individually.  
 Areas of future study with fondaparinus should focus on elderly patients who are at 
greater risk of DVT, closer evaluation of its use in pulmonary embolus, and post coronary 
stent (these trials are ongoing at this time). Additionally, a comparison of fondaparinux to 
enoxaparin in traumatic versus elective surgery may provide quality information for use in 
emergent situations. Trials determining the safety and efficacy of fondaparinux in the elderly 
population with renal impairment may be of paramount importance in the future.  
 
Conclusion 
 Based on the results of the articles reviewed for this study, fondaparinux provides 
greater DVT prophylaxis when compared to enoxaparin in lower extremity orthopedic 
surgery. Fondaparinux caused no increase in major or clinically relevant bleeding. Its ease of 
administration (once daily compared to twice daily with enoxaparin), linear 
pharmacokinetics, and long half-life (17 hours) improve patient and clinician compliance and 
outcomes. As of this writing, both enoxaparin (7 to 10 days with extended prophylaxis to 35 
days) and fondaparinux (5 to nine days) are approved for DVT prophylaxis in hip and/or 
knee surgery patients17.  
 Current clinical trials are investigating the efficacy of fondaparinux in coronary 
surgery and stent placement, abdominal surgery, DVT prophylaxis in cancer treatment, and 
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extended DVT prophylaxis in orthopedic surgery. Finally, fondaparinux received a Grade Ia 
recommendation for DVT prophylaxis in hip fracture surgery, total hip arthroplasty, and total 
knee replacement in the 8th Edition of Antithrombotic and Thrombolytic Therapy guidelines 
by the American College of Chest Physicians.18 Lastly, and maybe most importantly, 
government agencies as noted by Gordois, et al8 and insurance companies (Blue Cross Blue 
Shield in particular) have noted evidence of cost savings in the short and long-term with the 
use of fondaparinux, even to the extent that this medication is now considered “medically 
necessary” in the prevention of DVT for hip and knee surgery patients.19 Undoubtedly, cost 
savings along with improved patient outcomes will provide the incentive for increased use of 
fondaparinux as well as additional impetus for further study.  
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Table I: Results of Reviewed Articles 
Study Published Study 
Type 
Sample Size Comparison Results 
Dose-ranging 
trial10 
2001 Double 
blind 
933 hip 
replacement 
patients 
Various doses 
of fondaparinux 
(up to 8 mg 
daily) to 
enoxaparin 30 
mg twice daily 
Fondaparinux  
effective in 
DVT 
prevention in 
THR patients; 
lower bleeding 
risk than 
enoxaparin 
PENTAMAKS14 2001 Double 
blind, 
randomly 
assigned 
1049 major 
knee 
surgery 
patients  
Fondaparinux 
2.5 mg once 
daily compared 
to enoxaparin 
30 mg twice 
daily; both 
given 
postoperative 
fondaparinux 
produced RRR 
of 55.2% 
compared to 
enoxaparin 
EPHESUS11 2002 Double 
blind, 
randomly 
assigned 
2309 hip 
replacement 
patients 
Postoperative 
fondaparinux 
2.5 mg once 
daily to 
preoperative 
enoxaparin 40 
mg once daily 
Fondaparinux  
produced RRR 
of 56%  
compared to 
enoxaparin  
PENTATHLON 
200012 
2002 Double 
blind, 
randomly 
assisgned 
2275 hip 
replacement 
patients 
Fondaparinux 
2.5 mg once 
daily to 
enoxaparin 30 
mg twice daily; 
both started 
postoperative 
Fondaparinux 
produced RRR 
of 26.3%  
compared to 
enoxaparin 
PENTHIFRA13 2002 Double 
blind, 
randomly 
assigned 
1711 hip 
fracture 
surgery 
patients 
Postoperative 
fondaparinux 
2.5 mg once 
daily to 
preoperative 
enoxaparin 
Fondaparinux 
produced RRR 
of 56.4%  
compared to 
enoxaparin 
PENTHIFRA 
Plus15 
2003 Double 
blind 
656 hip 
fracture 
surgery 
patients 
Postoperative 
fondaparinux 
2.5 mg once 
daily to placebo 
Fondaparinux 
produced RR 
of 96% versus 
placebo 
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Figure I: Coagulation cascade and mechanism of action of fondaparinux 20. 
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